LAMEA Retinal Biologics Market Size, Share & Industry Trends Analysis Report By Indication (Macular Degeneration, Diabetic Retinopathy), By Drug Class (VEGF-A Antagonist and Others), By Distribution Channel, By Country and Growth Forecast, 2023

List of Tables

The Latin America, Middle East and Africa Retinal Biologics Market would witness market growth of 6.3% CAGR during the forecast period (2023-2030).

Growing consumer awareness of retinal illnesses, how to diagnose them, and the therapies that are available has been a major factor in the market expansion. In order to raise awareness, fund research, and offer assistance to sufferers and their families, organizations like the American Macular Degeneration Foundation (AMDF) and the Foundation Fighting Blindness are vital. The activities of these organizations help raise public awareness, which in turn helps the market expand. The market is also expanding due to factors like the increased use of VEGF-A antagonists and greater awareness of early diagnosis and treatment.

Moreover, developments in molecular biology, genetic engineering, and biotechnology have created new opportunities for creating retinal biologic medicines. In preclinical and clinical investigations, methods like gene therapy, cell-based therapeutics, and RNA interference have demonstrated promise, igniting research and development efforts in retinal biologics and fostering the market's expansion.

Throughout the projection period, the market in Latin America is anticipated to expand. Some of the primary drivers behind the expansion of the market in the region include the rising prevalence of various eye-related problems, the general public's increased awareness of diseases, and the leading players' increasing efforts to introduce new drugs there. The demand for therapies for ocular diseases is developing in Latin America and the Middle East & Africa due to a number of factors, including bettering healthcare infrastructure and expanding collaboration and partnerships among the major players to enhance access to diverse ophthalmic medications.

Similarly, in the Middle East, Bahrain, Kuwait, Lebanon, Oman, Saudi Arabia, and the United Arab Emirates are six of the ten nations in the world with the highest prevalence of diabetes. From 19% in the UAE to 64% in Jordan, diabetic retinopathy is common. Consequently, this has presented numerous growth opportunities for key market players and thus propel the development of the regional market.

The Brazil market dominated the LAMEA Retinal Biologics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $236.4 million by 2030. The Argentina market is showcasing a CAGR of 6.9% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 6% during (2023 - 2030).

Based on Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy and Others. Based on Drug Class, the market is segmented into VEGF-A Antagonist and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Amgen, Inc., AbbVie, Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., MeiraGTx Holdings plc and Oxurion NV.

Scope of the Study

Market Segments covered in the Report:

By Indication

Macular Degeneration
Diabetic Retinopathy
Others

By Drug Class

VEGF-A Antagonist
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Country

Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Companies Profiled

Novartis AG
Amgen, Inc.
AbbVie, Inc.
Bayer AG
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
MeiraGTx Holdings plc
Oxurion NV

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 LAMEA Retinal Biologics Market, by Indication
- 1.4.2 LAMEA Retinal Biologics Market, by Drug Class
- 1.4.3 LAMEA Retinal Biologics Market, by Distribution Channel
- 1.4.4 LAMEA Retinal Biologics Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
3.3 Porter's Five Forces Analysis

Chapter 4. Strategies deployed in Retinal Biologics Market

Chapter 5. LAMEA Retinal Biologics Market by Indication

5.1 LAMEA Macular Degeneration Market by Country
5.2 LAMEA Diabetic Retinopathy Market by Country
5.3 LAMEA Others Market by Country

Chapter 6. LAMEA Retinal Biologics Market by Drug Class

6.1 LAMEA VEGF-A Antagonist Market by Country
6.2 LAMEA Others Market by Country

Chapter 7. LAMEA Retinal Biologics Market by Distribution Channel

7.1 LAMEA Hospital Pharmacy Market by Country
7.2 LAMEA Retail Pharmacy Market by Country
7.3 LAMEA Online Pharmacy Market by Country

Chapter 8. LAMEA Retinal Biologics Market by Country

8.1 Brazil Retinal Biologics Market
- 8.1.1 Brazil Retinal Biologics Market by Indication
- 8.1.2 Brazil Retinal Biologics Market by Drug Class
- 8.1.3 Brazil Retinal Biologics Market by Distribution Channel
8.2 Argentina Retinal Biologics Market
- 8.2.1 Argentina Retinal Biologics Market by Indication
- 8.2.2 Argentina Retinal Biologics Market by Drug Class
- 8.2.3 Argentina Retinal Biologics Market by Distribution Channel
8.3 UAE Retinal Biologics Market
- 8.3.1 UAE Retinal Biologics Market by Indication
- 8.3.2 UAE Retinal Biologics Market by Drug Class
- 8.3.3 UAE Retinal Biologics Market by Distribution Channel
8.4 Saudi Arabia Retinal Biologics Market
- 8.4.1 Saudi Arabia Retinal Biologics Market by Indication
- 8.4.2 Saudi Arabia Retinal Biologics Market by Drug Class
- 8.4.3 Saudi Arabia Retinal Biologics Market by Distribution Channel
8.5 South Africa Retinal Biologics Market
- 8.5.1 South Africa Retinal Biologics Market by Indication
- 8.5.2 South Africa Retinal Biologics Market by Drug Class
- 8.5.3 South Africa Retinal Biologics Market by Distribution Channel
8.6 Nigeria Retinal Biologics Market
- 8.6.1 Nigeria Retinal Biologics Market by Indication
- 8.6.2 Nigeria Retinal Biologics Market by Drug Class
- 8.6.3 Nigeria Retinal Biologics Market by Distribution Channel
8.7 Rest of LAMEA Retinal Biologics Market
- 8.7.1 Rest of LAMEA Retinal Biologics Market by Indication
- 8.7.2 Rest of LAMEA Retinal Biologics Market by Drug Class
- 8.7.3 Rest of LAMEA Retinal Biologics Market by Distribution Channel

Chapter 9. Company Profiles

9.1 Novartis AG
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Segmental and Regional Analysis
- 9.1.4 Research & Development Expense
- 9.1.5 Recent strategies and developments:
  - 9.1.5.1 Acquisition and Mergers:
- 9.1.6 SWOT Analysis
9.2 Amgen, Inc.
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Regional Analysis
- 9.2.4 Research & Development Expenses
- 9.2.5 SWOT Analysis
9.3 AbbVie, Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Regional Analysis
- 9.3.4 Research & Development Expense
- 9.3.5 Recent strategies and developments:
  - 9.3.5.1 Partnerships, Collaborations, and Agreements:
  - 9.3.5.2 Approvals & Trials:
- 9.3.6 SWOT Analysis
9.4 Bayer AG
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Segmental and Regional Analysis
- 9.4.4 Research & Development Expense
- 9.4.5 SWOT Analysis
9.5 Regeneron Pharmaceuticals, Inc.
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Research & Development Expense
- 9.5.4 SWOT Analysis
9.6 Santen Pharmaceutical Co., Ltd.
- 9.6.1 Company Overview
- 9.6.2 Financial Analysis
- 9.6.3 Regional Analysis
- 9.6.4 Research & Development Expenses
- 9.6.5 SWOT Analysis
9.7 Bausch Health Companies, Inc.
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Segmental and Regional Analysis
- 9.7.4 Research & Development Expense
- 9.7.5 Recent strategies and developments:
  - 9.7.5.1 Partnerships, Collaborations, and Agreements:
  - 9.7.5.2 Approvals & Trials:
  - 9.7.5.3 Acquisition and Mergers:
- 9.7.6 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
- 9.8.1 Company Overview
- 9.8.2 Financial Analysis
- 9.8.3 Segmental and Regional Analysis
- 9.8.4 Research & Development Expense
- 9.8.5 Recent strategies and developments:
  - 9.8.5.1 Partnerships, Collaborations, and Agreements:
  - 9.8.5.2 Approvals & Trials:
- 9.8.6 SWOT Analysis
9.9 MeiraGTx Holdings plc
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Research & Development Expenses
- 9.9.4 SWOT Analysis
9.10. Oxurion NV
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Research & Development Expenses
- 9.10.4 SWOT Analysis

LIST OF TABLES

TABLE 1 LAMEA Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 3 LAMEA Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 4 LAMEA Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 5 LAMEA Macular Degeneration Market by Country, 2019 - 2022, USD Million
TABLE 6 LAMEA Macular Degeneration Market by Country, 2023 - 2030, USD Million
TABLE 7 LAMEA Diabetic Retinopathy Market by Country, 2019 - 2022, USD Million
TABLE 8 LAMEA Diabetic Retinopathy Market by Country, 2023 - 2030, USD Million
TABLE 9 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 11 LAMEA Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 12 LAMEA Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 13 LAMEA VEGF-A Antagonist Market by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA VEGF-A Antagonist Market by Country, 2023 - 2030, USD Million
TABLE 15 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 16 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 17 LAMEA Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 LAMEA Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 LAMEA Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 21 LAMEA Retail Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 22 LAMEA Retail Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 23 LAMEA Online Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Online Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 25 LAMEA Retinal Biologics Market by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA Retinal Biologics Market by Country, 2023 - 2030, USD Million
TABLE 27 Brazil Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 28 Brazil Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 29 Brazil Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 30 Brazil Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 31 Brazil Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 32 Brazil Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 33 Brazil Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 Brazil Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 Argentina Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 36 Argentina Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 37 Argentina Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 38 Argentina Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 39 Argentina Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 40 Argentina Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 41 Argentina Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Argentina Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 UAE Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 44 UAE Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 45 UAE Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 46 UAE Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 47 UAE Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 48 UAE Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 49 UAE Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 UAE Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Saudi Arabia Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 52 Saudi Arabia Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 53 Saudi Arabia Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 54 Saudi Arabia Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 55 Saudi Arabia Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 56 Saudi Arabia Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 57 Saudi Arabia Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Saudi Arabia Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 South Africa Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 60 South Africa Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 61 South Africa Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 62 South Africa Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 63 South Africa Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 64 South Africa Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 65 South Africa Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 South Africa Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Nigeria Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 68 Nigeria Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 69 Nigeria Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 70 Nigeria Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 71 Nigeria Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 72 Nigeria Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 73 Nigeria Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Nigeria Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Rest of LAMEA Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 76 Rest of LAMEA Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 77 Rest of LAMEA Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 78 Rest of LAMEA Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 79 Rest of LAMEA Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 80 Rest of LAMEA Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 81 Rest of LAMEA Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Rest of LAMEA Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Key Information - Novartis AG
TABLE 84 Key Information - Amgen, Inc.
TABLE 85 Key information - AbbVie, Inc.
TABLE 86 Key Information - Bayer AG
TABLE 87 Key Information - Regeneron Pharmaceuticals, Inc.
TABLE 88 Key Information - Santen Pharmaceutical Co., Ltd.
TABLE 89 key information - Bausch Health Companies, Inc.
TABLE 90 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
TABLE 91 Key Information - MeiraGTx Holdings plc
TABLE 92 Key Information - Oxurion NV

List of Figures

FIG 1 Methodology for the research
FIG 2 LAMEA Retinal Biologics Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Retinal Biologics Market
FIG 4 Porter's Five Forces Analysis - Retinal Biologics Market
FIG 5 LAMEA Retinal Biologics Market share by Indication, 2022
FIG 6 LAMEA Retinal Biologics Market share by Indication, 2030
FIG 7 LAMEA Retinal Biologics Market by Indication, 2019 - 2030, USD Million
FIG 8 LAMEA Retinal Biologics Market share by Drug Class, 2022
FIG 9 LAMEA Retinal Biologics Market share by Drug Class, 2030
FIG 10 LAMEA Retinal Biologics Market by Drug Class, 2019 - 2030, USD Million
FIG 11 LAMEA Retinal Biologics Market share by Distribution Channel, 2022
FIG 12 LAMEA Retinal Biologics Market share by Distribution Channel, 2030
FIG 13 LAMEA Retinal Biologics Market by Distribution Channel, 2019 - 2030, USD Million
FIG 14 LAMEA Retinal Biologics Market share by Country, 2022
FIG 15 LAMEA Retinal Biologics Market share by Country, 2030
FIG 16 LAMEA Retinal Biologics Market by Country, 2019 - 2030, USD Million
FIG 17 SWOT Analysis: Novartis AG
FIG 18 Swot Analysis: Amgen, Inc.
FIG 19 Swot Analysis: AbbVie, Inc.
FIG 20 Swot Analysis: Bayer AG
FIG 21 Swot Analysis: Regeneron Pharmaceuticals, Inc.
FIG 22 Swot Analysis: Santen Pharmaceutical Co., Ltd.
FIG 23 Recent strategies and developments: Bausch Health Companies, Inc.
FIG 24 Swot Analysis: Bausch Health Companies, Inc.
FIG 25 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 26 Swot Analysis: MeiraGTx Holdings plc
FIG 27 Swot Analysis: Oxurion NV

LAMEA Retinal Biologics Market Size, Share & Industry Trends Analysis Report By Indication (Macular Degeneration, Diabetic Retinopathy), By Drug Class (VEGF-A Antagonist and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents